Cargando…
FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century
Fibroblast activation protein (FAP), a type II transmembrane serine protease, is highly expressed in more than 90% of epithelial tumors and is closely associated with various tumor invasion, metastasis, and prognosis. Using FAP as a target, various FAP inhibitors (FAPIs) have been developed, most of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174525/ https://www.ncbi.nlm.nih.gov/pubmed/35692767 http://dx.doi.org/10.3389/fonc.2022.854658 |
_version_ | 1784722254426275840 |
---|---|
author | Huang, Rong Pu, Yu Huang, Shun Yang, Conghui Yang, Fake Pu, Yongzhu Li, Jindan Chen, Long Huang, Yunchao |
author_facet | Huang, Rong Pu, Yu Huang, Shun Yang, Conghui Yang, Fake Pu, Yongzhu Li, Jindan Chen, Long Huang, Yunchao |
author_sort | Huang, Rong |
collection | PubMed |
description | Fibroblast activation protein (FAP), a type II transmembrane serine protease, is highly expressed in more than 90% of epithelial tumors and is closely associated with various tumor invasion, metastasis, and prognosis. Using FAP as a target, various FAP inhibitors (FAPIs) have been developed, most of which have nanomolar levels of FAP affinity and high selectivity and are used for positron emission tomography (PET) imaging of different tumors. We have conducted a systematic review of the available data; summarized the biological principles of FAPIs for PET imaging, the synthesis model, and metabolic characteristics of the radiotracer; and compared the respective values of FAPIs and the current mainstream tracer (18)F-Fludeoxyglucose ((18)F-FDG) in the clinical management of tumor and non-tumor lesions. Available research evidence indicates that FAPIs are a molecular imaging tool complementary to (18)F-FDG and are expected to be the new molecule of the century with better imaging effects than (18)F-FDG in a variety of cancers, including gastrointestinal tumors, liver tumors, breast tumors, and nasopharyngeal carcinoma. |
format | Online Article Text |
id | pubmed-9174525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91745252022-06-09 FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century Huang, Rong Pu, Yu Huang, Shun Yang, Conghui Yang, Fake Pu, Yongzhu Li, Jindan Chen, Long Huang, Yunchao Front Oncol Oncology Fibroblast activation protein (FAP), a type II transmembrane serine protease, is highly expressed in more than 90% of epithelial tumors and is closely associated with various tumor invasion, metastasis, and prognosis. Using FAP as a target, various FAP inhibitors (FAPIs) have been developed, most of which have nanomolar levels of FAP affinity and high selectivity and are used for positron emission tomography (PET) imaging of different tumors. We have conducted a systematic review of the available data; summarized the biological principles of FAPIs for PET imaging, the synthesis model, and metabolic characteristics of the radiotracer; and compared the respective values of FAPIs and the current mainstream tracer (18)F-Fludeoxyglucose ((18)F-FDG) in the clinical management of tumor and non-tumor lesions. Available research evidence indicates that FAPIs are a molecular imaging tool complementary to (18)F-FDG and are expected to be the new molecule of the century with better imaging effects than (18)F-FDG in a variety of cancers, including gastrointestinal tumors, liver tumors, breast tumors, and nasopharyngeal carcinoma. Frontiers Media S.A. 2022-05-25 /pmc/articles/PMC9174525/ /pubmed/35692767 http://dx.doi.org/10.3389/fonc.2022.854658 Text en Copyright © 2022 Huang, Pu, Huang, Yang, Yang, Pu, Li, Chen and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Huang, Rong Pu, Yu Huang, Shun Yang, Conghui Yang, Fake Pu, Yongzhu Li, Jindan Chen, Long Huang, Yunchao FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century |
title | FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century |
title_full | FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century |
title_fullStr | FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century |
title_full_unstemmed | FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century |
title_short | FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century |
title_sort | fapi-pet/ct in cancer imaging: a potential novel molecule of the century |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174525/ https://www.ncbi.nlm.nih.gov/pubmed/35692767 http://dx.doi.org/10.3389/fonc.2022.854658 |
work_keys_str_mv | AT huangrong fapipetctincancerimagingapotentialnovelmoleculeofthecentury AT puyu fapipetctincancerimagingapotentialnovelmoleculeofthecentury AT huangshun fapipetctincancerimagingapotentialnovelmoleculeofthecentury AT yangconghui fapipetctincancerimagingapotentialnovelmoleculeofthecentury AT yangfake fapipetctincancerimagingapotentialnovelmoleculeofthecentury AT puyongzhu fapipetctincancerimagingapotentialnovelmoleculeofthecentury AT lijindan fapipetctincancerimagingapotentialnovelmoleculeofthecentury AT chenlong fapipetctincancerimagingapotentialnovelmoleculeofthecentury AT huangyunchao fapipetctincancerimagingapotentialnovelmoleculeofthecentury |